Partnership will exploit ICON’s global reach and Tigermed’s local knowledge of Chinese drug development.

Outsourced development services company ICON and clinical development services firm Tigermed Consulting entered into an alliance that they suggest will help their pharma and biotech clients gain better access to Chinese patient populations. The companies report that the partnership will combine ICON’s global reach and experience with Tigermed’s knowledge of the Chinese drug development landscape and geography.

News of the alliance comes less than a month after Ireland-based ICON opened an office in Manila, Philippines, as part of its continued drive into Asian markets. This announcement followed the recent expansion of ICON’s operations in Seoul and a move in mid-2009 to a larger laboratory facility in Singapore.

Tigermed has 21 offices in China and employs some 300 clinical development support staff. “Tigermed has a substantial clinical operations presence on the Chinese mainland, and this experience gives them the ability to provide wide-ranging support for clinical drug development services in China,” states John Hubbard, Ph.D., ICON group president.

“This alliance enhances our regional and global capabilities and will enable both ICON and Tigermed to expand the range of clinical research services we can offer to clients in China and around the globe,” adds Xiaoping Ye, chairman and CEO at Tigermed.

Previous articleRecordati Signs Up Esteve as Marketing Partner for Pitavastatin in Spain
Next articleAchaogen Completes $56M Fund-Raising to Take Neoglycoside Antibiotic into Phase II